X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs AUROBINDO PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA AUROBINDO PHARMA CIPLA/
AUROBINDO PHARMA
 
P/E (TTM) x 44.6 14.6 304.5% View Chart
P/BV x 3.8 3.8 101.7% View Chart
Dividend Yield % 0.3 0.4 80.9%  

Financials

 CIPLA   AUROBINDO PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
AUROBINDO PHARMA
Mar-17
CIPLA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs622895 69.5%   
Low Rs458622 73.7%   
Sales per share (Unadj.) Rs181.9254.6 71.4%  
Earnings per share (Unadj.) Rs12.939.3 32.8%  
Cash flow per share (Unadj.) Rs29.346.6 62.9%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.40.3 112.3%  
Book value per share (Unadj.) Rs155.7160.0 97.3%  
Shares outstanding (eoy) m804.51585.88 137.3%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.03.0 99.7%   
Avg P/E ratio x42.019.3 217.3%  
P/CF ratio (eoy) x18.416.3 113.1%  
Price / Book Value ratio x3.54.7 73.2%  
Dividend payout %15.56.4 244.1%   
Avg Mkt Cap Rs m434,516444,390 97.8%   
No. of employees `00023.014.0 164.8%   
Total wages/salary Rs m26,33817,678 149.0%   
Avg. sales/employee Rs Th6,349.110,667.8 59.5%   
Avg. wages/employee Rs Th1,143.01,264.3 90.4%   
Avg. net profit/employee Rs Th449.31,645.8 27.3%   
INCOME DATA
Net Sales Rs m146,302149,157 98.1%  
Other income Rs m2,2871,159 197.3%   
Total revenues Rs m148,589150,316 98.9%   
Gross profit Rs m24,75834,343 72.1%  
Depreciation Rs m13,2294,276 309.4%   
Interest Rs m1,594667 238.9%   
Profit before tax Rs m12,22230,558 40.0%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7987,597 23.7%   
Profit after tax Rs m10,35423,012 45.0%  
Gross profit margin %16.923.0 73.5%  
Effective tax rate %14.724.9 59.2%   
Net profit margin %7.115.4 45.9%  
BALANCE SHEET DATA
Current assets Rs m87,37092,062 94.9%   
Current liabilities Rs m33,08166,223 50.0%   
Net working cap to sales %37.117.3 214.2%  
Current ratio x2.61.4 190.0%  
Inventory Days Days87106 82.1%  
Debtors Days Days6268 92.1%  
Net fixed assets Rs m111,56762,919 177.3%   
Share capital Rs m1,609586 274.6%   
"Free" reserves Rs m123,64593,133 132.8%   
Net worth Rs m125,25493,719 133.6%   
Long term debt Rs m36,4541,814 2,009.6%   
Total assets Rs m209,532162,494 128.9%  
Interest coverage x8.746.8 18.5%   
Debt to equity ratio x0.30 1,503.6%  
Sales to assets ratio x0.70.9 76.1%   
Return on assets %5.714.6 39.1%  
Return on equity %8.324.6 33.7%  
Return on capital %8.532.7 26.0%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06675,838 67.3%   
Fx outflow Rs m17,67830,224 58.5%   
Net fx Rs m33,38845,613 73.2%   
CASH FLOW
From Operations Rs m23,82432,786 72.7%  
From Investments Rs m-13,127-17,870 73.5%  
From Financial Activity Rs m-13,239-19,153 69.1%  
Net Cashflow Rs m-2,478-4,239 58.5%  

Share Holding

Indian Promoters % 16.0 54.1 29.6%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.0 153.5%  
FIIs % 23.7 27.7 85.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.2 256.9%  
Shareholders   161,166 69,601 231.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 23, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS